Following a 4-day treatment, the number of Ki-67-positive proliferating tumor cells did not differ significantly between the lorlatinib- or combination-treated tumors derived from A925L and H2228 cells, respectively (Fig. 6c, d). The gene discussed is MKI67; the disease is neoplasm.